Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain

By Meg Flippin Benzinga

BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to achieve those goals. The company’s flagship product candidate, BRTX-100, just completed a phase 2 clinical trial for chronic lumbar disc disease (cLDD), which Alstodt was on hand to discuss with Benzinga.

“Data from the first 36 patients was highly encouraging," Alstodt told Benzinga in the interview. “At 52 weeks over 74% of participants demonstrated greater than 50% improvement in function and over 72% reported a greater than 50% reduction in pain, both substantially exceeding the FDA’s clinically meaningful threshold of 30%,” Alstodt said the phase 2 outcome set the stage for a pivotal trial or even accelerated path to approval. 

BRTX-100 is an autologous stem cell product for chronic lower back pain. It uses a patient’s stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. During the interview, Alstodt told Benzinga that he thinks what makes BRTX-100 different is that instead of masking the pain, like opioids and injectables, the BioRestorative product candidate is targeting the root cause. The goal of the phase 2 trials is to enroll a total of 99 patients, which the CEO said is tracking well. An announcement on that front is expected soon. 

But that’s not all Alstodt revealed in this wide-ranging interview. From BioRestorative’s expansion plans to what’s next for the company, the executive had a lot to share in this must-watch All Access interview. 

Watch the full interview here: 

https://www.youtube.com/watch?v=7NrNkBtUT4s

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.